South African Health Legislation Withdrawn

18 June 1997

South African Health Minister Nkosazana Zuma has apparently yielded tooverwhelming local and international pressure and withdrawn three controversial bills, including the Medicines and Related Substances Control Amendment Bill which would have legalized generic substitution and parallel imports.

Dr Zuma said that the bills, which would also introduce two years' vocational training for medical students and permit lay ownership of pharmacies, would now be resubmitted to the cabinet for approval this month.

The withdrawal means another round of public hearings must be held once the bills are resubmitted to parliament. Dr Zuma's decision to resend them through the parliamentary process follows strong opposition from political parties, the pharmaceutical industry, medical students and foreign firms with interests in the South African health care industry (Marketletter June 9), plus accusations that she had tried to steamroller them through parliament.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight